NCT04322656

Stability of Biometry in Meibomian Gland Dysfunction

Stability of Biometry in Patients With Meibomian Gland Dysfunction

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 31 (estimated)
• Sponsor: Vienna Institute for Research in Ocular Surgery · Academic / Other
• Sex: All
• Age: 21 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

Accurate biometry is an essential and indispensable tool in preoperative cataract surgery setting to yield optimal postoperative refractive outcome. However, some recent studies indicate that preoperative biometry is influenced by dry eye disease (DED). Hence, the investigator's study aims to investigate the effect of the therapy of MGD using the Lipiflow® device on the stability of biometry and selection of IOL.

Detailed description

Accurate biometry is an essential and indispensable tool in preoperative cataract surgery setting to yield optimal postoperative refractive outcome. 31 Patients suffering from DED caused by MGD will be selected and allocated randomly to therapy. Patients with pre-existing DED therapy other than lubricants will be excluded. After completing prestudy-screening and baseline visit, Lipiflow® therapy is applied to the study eye. Follow-up visits will be scheduled two weeks and three months after baseline visit. Each visit includes dry eye investigations and IOL calculation by IOLmaster 700 and CSO MS-39. After each study visit an IOL will be theoretically selected.

Conditions

• Meibomian Gland Dysfunction

Interventions

Type	Name	Description
DEVICE	Lipiflow treatment	Patients will be treated on one eye with Lipiflow

Timeline

• Start date: 2020-02-06
• Primary completion: 2023-03-31
• Completion: 2023-09-30
• First posted: 2020-03-26
• Last updated: 2022-10-17

Locations

1 site across 1 country: Austria